Patents by Inventor Matthew J. Bernett

Matthew J. Bernett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND GPC3
    Publication number: 20220306767
    Abstract: Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 29, 2022
    Inventors: Alex Nisthal, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Matthew J. Bernett, Rajat Varma
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6
    Publication number: 20220289839
    Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 15, 2022
    Inventors: Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
  • ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
    Publication number: 20220227867
    Abstract: The present invention is directed to novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a ICOS antibody fragment-Fc fusion protein.
    Type: Application
    Filed: December 23, 2021
    Publication date: July 21, 2022
    Inventors: Matthew J. Bernett, John R. Desjarlais, Gregory Moore, Suzanne Schubbert
  • Heterodimeric antibodies that bind CD3 and CD38
    Patent number: 11352442
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • CTLA4-IG immunoadhesins
    Patent number: 11352412
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20220162343
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: December 3, 2021
    Publication date: May 26, 2022
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS
    Publication number: 20220073588
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.
    Type: Application
    Filed: July 2, 2021
    Publication date: March 10, 2022
    Inventors: Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
  • CTLA4-Ig immunoadhesins
    Patent number: 11254727
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: February 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20220041757
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: October 18, 2021
    Publication date: February 10, 2022
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11225528
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: January 18, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
    Publication number: 20210284754
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Application
    Filed: October 12, 2020
    Publication date: September 16, 2021
    Inventors: Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11111315
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS
    Publication number: 20210253706
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Application
    Filed: April 16, 2021
    Publication date: August 19, 2021
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
    Patent number: 11084863
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 10, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20210230250
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: April 15, 2021
    Publication date: July 29, 2021
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20210102003
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 8, 2021
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 10913803
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 9, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 10889653
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 12, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Bispecific antibodies that bind to CD38 and CD3
    Patent number: 10858451
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: December 8, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Y. Chu, Gregory Moore, John Desjarlais
  • Heterodimeric human IgG1 polypeptides with isoelectric point modifications
    Patent number: 10851178
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: December 1, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid